Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer

被引：8
作者：
Osterweil, Neil
机构：
来源：
CANCER DISCOVERY | 2022年 / 12卷 / 04期
关键词：
D O I：
10.1158/2159-8290.CD-NB2022-0015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：878 / 879
页数：2
相关论文
共 50 条
  • [41] Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
    Oliver, Timothee
    Haslam, Alyson
    Prasad, Vinay
    TRANSLATIONAL ONCOLOGY, 2023, 28
  • [42] Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer
    Ganguly, Arghya
    Yoo, Euna
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (06) : 536 - 537
  • [43] KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
    Hong, David S.
    Fakih, Marwan G.
    Strickler, John H.
    Desai, Jayesh
    Durm, Gregory A.
    Shapiro, Geoffrey I.
    Falchook, Gerald S.
    Price, Timothy J.
    Sacher, Adrian
    Denlinger, Crystal S.
    Bang, Yung-Jue
    Dy, Grace K.
    Krauss, John C.
    Kuboki, Yasutoshi
    Kuo, James C.
    Coveler, Andrew L.
    Park, Keunchil
    Kim, Tae Won
    Barlesi, Fabrice
    Munster, Pamela N.
    Ramalingam, Suresh S.
    Burns, Timothy F.
    Meric-Bernstam, Funda
    Henary, Haby
    Ngang, Jude
    Ngarmchamnanrith, Gataree
    Kim, June
    Houk, Brett E.
    Canon, Jude
    Lipford, J. Russell
    Friberg, Gregory
    Lito, Piro
    Govindan, Ramaswamy
    Li, Bob T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (13) : 1207 - 1217
  • [44] Sotorasib/SHP2 inhibitors combo, KRASG12C(ON)I and RASMULTI(ON)I effectively target KRASG12C tumors developing secondary resistance to Sotorasib via KRASG12C amplification
    Solanki, Hitendra S.
    Imbody, Denis
    Desai, Bina
    Kato, Ryoji
    Stewart, Paul A.
    Stern, Yaakov
    Majumder, Anurima
    Bridenstine, Liznair
    Sarca, Bhaswati
    Miroshnychenko, Dada
    Aronchik, Ida
    Marusyk, Andriy
    Haura, Eric B.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [45] Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review (vol 8, e2300644, 2024)
    Luo, Jia
    JCO PRECISION ONCOLOGY, 2024, 8
  • [46] BAYESIAN PAN-TUMOR MULTILEVEL META-REGRESSION: AN UNANCHORED INDIRECT TREATMENT COMPARISON (ITC) OF ADAGRASIB VERSUS SOTORASIB IN PREVIOUSLY TREATED KRASG12C-MUTATED ADVANCED/METASTATIC SOLID TUMORS
    Maciel, D.
    Bouwmeester, W.
    Korytowsky, B.
    Campbell, H.
    Jevdjevic, M.
    Qian, C.
    Alejandro, L.
    Laurie, M.
    Patel, R.
    Gao, S.
    Jansen, J.
    Cope, S.
    VALUE IN HEALTH, 2024, 27 (06) : S32 - S32
  • [47] Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
    Felip, E.
    Mok, T. S. K.
    Lu, S.
    Barlesi, F.
    Jotte, R.
    Lo Russo, G.
    Reck, M.
    Yao, W.
    Doucet, L.
    Martinez, A. Azkarate
    Gregorc, V.
    Juan-Vidal, O.
    Raskin, J.
    Linardou, H.
    Raina, R.
    Penton, H.
    Lee, A.
    Blum, S. I.
    Korytowsky, B.
    Duruisseaux, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S30 - S30
  • [48] SOTORASIB IS ACTIVE IN KRASG12C-MUTANT NON-SMALL CELL LUNG CANCER
    Skoulidis, F.
    Li, B. T.
    Dy, G. K.
    Price, T. J.
    Falchook, G. S.
    Wolf, J.
    CANCER DISCOVERY, 2021, 11 (08) : 1870 - 1870
  • [49] DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer
    Li-Wen Chiou
    Chien-Hui Chan
    Yu-Ling Jhuang
    Ching-Yao Yang
    Yung-Ming Jeng
    Journal of Biomedical Science, 30
  • [50] DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer
    Chiou, Li-Wen
    Chan, Chien-Hui
    Jhuang, Yu-Ling
    Yang, Ching-Yao
    Jeng, Yung-Ming
    CANCER RESEARCH, 2023, 83 (07)
12345